News & insights

Precision Oncology

Precision oncology matches each patient with the therapy most likely to work, based on the molecular profile of their tumor. For molecular labs, that means turning somatic NGS data into reliable, actionable results: detecting SNVs, indels and CNVs, and assessing genomic signatures such as HRD, MSI and TMB that guide treatment decisions.

In this section, we share our latest articles on precision oncology: case studies from labs using SeqOne for somatic analysis, scientific insights on biomarkers like homologous recombination deficiency, and updates on how our platform helps teams deliver faster, clinically validated cancer reports.

SeqOne Expands Into Preventive Genomics, With Pharmacogenomics Leading the Way

GermVar PGx, the first module of SeqOne Preventive Genomics, supports laboratories with pharmacogenomic analysis inside the germline workflow, from star-allele calling to the guideline recommendations their experts review and report.

SeqOne at ASHG 2026: Faster Answers, Fewer Blind Spots

Catch up on our ASHG 2026 CoLab and revisit the two posters presented by the SeqOne team, on DiagAI and UPD detection with GermVar.

The Fall 2026 Release is Here

SeqOne’s Fall 2026 Release brings a new PGx module, SomaHRD v2 and 80+ features and improvements, all IVD from day one, so labs can give more patients a clear answer, sooner, on a single platform.

SeqOne Receives C5:2020 Type 2 Attestation for Its Cloud Services

C5 is the BSI’s cloud security standard, required in Germany for health data. SeqOne’s cloud services now hold a C5:2020 Type 2 attestation, with security controls independently tested in day-to-day operations.

Bringing HRD Testing In-House: The Pathology Team in Valencia on Why They Made the Move

Valencia’s General University Hospital brought HRD testing in-house with Agilent and SeqOne. A 30-case study showed matching classifications vs. commercial assays, fewer inconclusive results, and turnaround cut from ~20 to 6-7 days.

SomaHRD v2 Raises the Bar on HRD Testing: 97.1% agreement with Myriad, and a status for 23 of the 26 samples it could not call.

SomaHRD v2 reaches 97.1% concordance with Myriad MyChoice CDx and a PFS hazard ratio of 0.23, with a 4.8% non-conclusive rate and results in 41 minutes.

Transparent AI for Germline Variant Prioritization: A Clinical Geneticist's Guide, featuring Uppsala University

Rewatch our webinar with Uppsala University Hospital: how one lab unified short-read, long-read, and array workflows on a single platform, and how transparent AI ranks variants so the geneticist stays in control.

When "No Variant Found" Was Not the Whole Answer

A clear DPYD test missed a 545kb deletion that caused severe chemotherapy toxicity in a cancer patient. SeqOne's copy number analysis helped confirm what standard testing couldn't see.

Precision medicine still overlooks most of the world. One Latin American lab is working to change that.

Precision medicine still overlooks most of the world. See how Gencell is closing that gap, one exome at a time.

Peer-Reviewed: DiagAI's Variant Prioritization, Validated

Every exome hides thousands of variants. See how DiagAI found the right one in 94.9% of cases, now peer-reviewed.

SeqOne at ESHG 2026: Advancing Variant Interpretation Through Research

Revisit the three posters presented by the SeqOne team at ESHG 2026.

AI in Rare Disease Diagnostics: Maintaining Accuracy, Compliance, and Trust

Genomic data is expanding rapidly. AI offers vital tools to streamline variant interpretation, but deploying it requires absolute clinical trust, rigorous compliance, and transparent decision-making.